HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVS shareholders seek cosmetics safety

This article was originally published in The Rose Sheet

Executive Summary

Reformulation of CVS private label cosmetic products to exclude "chemicals linked to cancer, mutations or birth defects" and review of "product ingredients for suspected carcinogens, mutagens, and reproductive toxins, and for chemicals that affect the endocrine system, accumulate in the body or persist in the environment" are among requests in shareholder resolution to be voted on during May 11 CVS Corp. annual meeting, according to Boston Common Asset Management, a primary filer of the document. Resolution also proposes CVS "proactively seek safe alternatives" for potentially unsafe chemicals and "encourage manufacturers or distributors of cosmetics products sold in CVS to do the same"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS013826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel